OCRF & Ovarian Cancer National Alliance are now one strong, united, inspiring voice!
Ovarian Cancer Research Fund (OCRF) and the Ovarian Cancer National Alliance (OCNA) have led the way in advocacy, research and support for patients and their families for over 22 years. As of January 2016, we are pleased to announce we are joining together to form Ovarian Cancer Research Fund Alliance (OCRFA), the largest global organization dedicated to advancing ovarian cancer research while supporting women and their families. Read the exciting news!

XClose

2003 Ann Schreiber Grant Recipient – Kuan-Chun Huang

Kuan-Chun Huang, Ph.D.
Brigham and Women’s Hospital
A Possible New Marker for Drug Resistance of Ovarian Cancer

Project Summary

For most ovarian cancer patients, a combination of surgery and postoperative chemotherapy is the standard of care. Chemotherapy consists of six cycles of Taxol and Carboplatin. In spite of a high response rate, many patients still develop and succumb to recurrent disease. Through a global genomic profiling study, Dr. Huang has identified that XIST (inactive X chromosome specific transcripts) gene expression level significantly correlates with Taxol sensitivity and disease-free periods of patients. From several lines of research, Dr. Huang hypothesizes that the RNA molecule that codes for XIST and the protein BRCA1, a breast and ovarian cancer tumor suppressor protein, interact and change the structure of the X chromosome to affect drug sensitivity of tumor cells. If so, the XIST RNA may be a prognostic marker of ovarian cancer, which Dr. Huang will study. She will also investigate in detail the interaction of the XIST RNA and BRCA1. Her findings should lead to a better understanding of drug response in ovarian cancer.